Human Insulin Market Forecasts from 2023 to 2028

The human insulin market was valued at US$20, 295.964 million in 2021.

The human insulin market is anticipated to grow at a steady pace. Human insulin is a medication of the hormone class. Human insulin is used in place of the insulin that the body normally generates. It works by facilitating the blood sugar's entry into various physiological tissues, where it serves as an energy source. Additionally, it stops the liver from producing more sugar. Additionally, populations who are older and fatter are more prone to chronic illnesses. The senior population worldwide was estimated by the World Bank Group to be over 727 703 million in 2020. Over the next three decades, this number is projected to quadruple, reaching almost 1.5 billion in 2050, which will propel the human insulin market.

Growth drivers for the human insulin market

Over the upcoming years, the human insulin market is anticipated to be driven by an increase in the number of diabetes patients and a rise in the demand for HI analogs. Additionally, optimistic medical reimbursement circumstances and growing diabetes awareness are anticipated to increase the human insulin market share in the next years. Additionally, it is anticipated that the introduction of pen devices and safety pen needles for efficient insulin delivery will drive the human insulin market growth throughout the anticipated period. Numerous organizations' increasing spending on R&D initiatives is probably what will drive the market's expansion.

Growing prevalence of diabetes

Every patient with type-1 diabetes and some people with type-2 diabetes need daily insulin injections as part of their therapy. According to the ADA, government insurance (including Medicare, Medicaid, and the military) covers about 67.3% of the cost of diabetes care in the United States. The remaining sum is covered by private insurance (30.7%) or uninsured individuals (2%). Between 2016 and 2022, the number of people with diabetes in Canada grew by almost 33%, and about 8% of those people have type-1 diabetes. The epidemiology of many emerging nations in North America, particularly those in the Caribbean, is changing, and the prevalence of diabetes is rising quickly.

Formulation advancements for insulin

A significant aspect influencing the expansion of space is developments in the formulation. For instance, Fiasp (Novo Nordisk) is a mixture of niacinamide (Vitamin-B3) and insulin aspart that can enhance the drug's early absorption. The only inhaled medication on the human insulin market that doesn't require syringes or needles is Afrezza (Mannkind). Phase 3 clinical studies are also being conducted for the oral insulin capsule made by Oramed Pharmaceuticals. The successful introduction of this product is anticipated to provide patients with another choice.

Rising investments in R&D activities

The global rise in diabetes and obesity cases, which are brought on by altered lifestyles and unhealthful sugar intake in a variety of foods and drinks, is what is driving the demand for human insulin. A sophisticated and simpler method of injecting insulin has also been made possible by the increased investments made in research and development activities by numerous organizations, which are also promoting human insulin market growth. Additionally, the development of safety pen devices and pen needles for efficient insulin delivery is advancing the worldwide industry. Furthermore, the need for human insulin is anticipated to increase as diabetes awareness grows.

Long-acting insulin is anticipated to be attributed to the largest market shareholder

Long-acting insulin is anticipated to be driven by elements like patent protection and strong demand due to long-term effects. Among the top goods in this category are Toujeo, Levemir, Xultophy, Insulatard, and Lantus. In contrast, insulin with a rapid onset of action promotes quicker absorption. Aspart, Lispro, and Glulisine are important items in this market.

During the projected period, the biosimilar human insulin market share is anticipated to grow at a profitable pace. The category growth will be fueled by the key products' patents expiring, as well as the following release and adoption of biosimilar insulin products. For instance, the FDA approved Semglee, a glargine biosimilar, in July 2021. It was the first interchangeable insulin biosimilar of Lantus to receive approval in the United States.

Rising prevalence of analogue insulin

The reason for analog insulin supremacy is that it is more effective than traditional therapy and has fewer side effects, such as fewer hypoglycemia spells and less weight gain. The majority of insulin medications are long-acting. Companies like Eli Lilly, Novo Nordisk A/S, and Sanofi respectively create long-acting insulin analogs including glargine, detemir, and degludec. These goods hold a sizable portion of the market, and demand for them is anticipated to fuel growth.

Human insulin, on the other hand, is the standard kind of insulin. Products like Humulin, Insuman, and Novolog are available on the market thanks to the top three producers. However, as more potent insulin analogs become available, it is anticipated that these medications' sales and prescription rates would fall during the ensuing years, fueling the human insulin market share.

North America is anticipated to dominate the human insulin market

North America, and specifically the United States, now hold a monopoly on the worldwide human insulin market due to the high incidence of diabetes in the region brought on by a sedentary lifestyle. In the United States, where nearly 50% of the earnings for the makers of insulin come from within the nation, the cost aspect is the main worry. The majority of long-acting insulin, Lantus, sold worldwide is in the United States. The majority of diabetic medicine producers view the nation as a crucial market for boosting overall worldwide sales. Lantus has a monopoly on the US market and is the most widely used basal insulin in the whole globe.

Key manufacturers are focusing on product innovation

The human insulin market is heavily concentrated, with only three big producers having a global presence and the rest limited to competing with other regional or local manufacturers. Recent mergers and acquisitions among the participants have aided the corporations in bolstering their market position. An agreement between Eli Lilly and Boehringer Ingelheim is being used to develop and market Basaglar (Insulin Glargine). Insulin Tregopil, an oral prandial insulin tablet, is being developed by Biocon to treat type-1 and type-2 diabetes mellitus. Fast-acting oral insulin holds the potential to revolutionize T1D care by enhancing postprandial glucose control with fewer side effects and higher adherence.

Market Key Developments

• In November 2022, Tzield (teplizumab-mzwv) injection was given the go-ahead by the U.S. Food and Drug Administration to postpone the beginning of stage 3 type-1 diabetics as well as stage 2 type-1 diabetic pediatric children 8 years of age and older.
• In May 2022, In addition to diet and exercise, the FDA authorized Lilly's new drug Mounjaro (also known as tirzepatide) for the treatment of type-2 diabetes. In clinical studies, this ground-breaking medicine significantly increased weight as well as glucose levels.

Segmentation:

By Product Type

• Rapid-Acting Insulin
• Long-Acting Insulin
• Combination Insulin
• Biosimilar
• Others

By Application

• Type 1 Diabetes Mellitus
• Type 2 Diabetes Mellitus

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others